Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue ...

Exact Sciences' management envisions blood-based testing as a viable alternative for those who decline both colonoscopy and Cologuard tests. Moreover, it is seen as a potential stepping stone for ...

Exact Sciences' management envisions blood-based testing as a viable alternative for those who decline both colonoscopy and Cologuard tests. Moreover, it is seen as a potential stepping stone for ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...

Exact Sciences released data from a study of its ... Exact, which makes the Cologuard fecal immunochemical test (FIT) test for colorectal cancer, said it is completing additional studies to ...

US diagnostic company Exact Sciences has announced its blood-based ... samples from the company’s pivotal BLUE-C study of its Cologuard Plus system which included more than 20,000 participants.

The results now are set to go alongside the company’s BLUE-C trial as part of an FDA submission for the cancer detecting ...